<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Recommendations</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Recommendations</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Recommendations</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kapil Kumar, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter J Zimetbaum, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Bradley P Knight, MD, FACC</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Susan B Yeon, MD, JD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 30, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>For patients with atrial fibrillation (AF), there are two main strategies to manage the irregular rhythm and its impact on symptoms: rhythm control (restoration followed by maintenance of sinus rhythm with either antiarrhythmic drugs or catheter ablation); and rate control with atrioventricular (AV) nodal blockers. (See <a class="local">'Initial management decisions'</a> below.)</p><p>For those patients in whom a rhythm control strategy is chosen, the main goal of therapy is to reduce symptoms by decreasing the frequency and duration of episodes as well as the symptoms during recurrences [<a href="#rid1">1,2</a>]. As antiarrhythmic drugs are associated with a potential for serious adverse side effects, particularly the induction of proarrhythmia, they should be prescribed only by practitioners familiar with their use. Patients should be fully informed of both the benefits and risks associated with the use of these drugs. (See <a class="local">'Drug-related arrhythmias and mortality'</a> below.)</p><p>Rhythm control can be achieved with either antiarrhythmic drug therapy or nonpharmacologic methods. This topic provides recommendations for the former. The clinical trials describing the efficacy and toxicity (including proarrhythmia) of the different antiarrhythmic drugs are presented separately. (See  <a class="medical medical_review" href="/z/d/html/1038.html" rel="external">"Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Clinical trials"</a>.)</p><p>Nonpharmacologic methods to maintain sinus rhythm (including surgery and radiofrequency ablation or cryoballoon ablation) in selected patients who are refractory to conventional therapy are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/949.html" rel="external">"Atrial fibrillation: Catheter ablation"</a> and  <a class="medical medical_review" href="/z/d/html/1046.html" rel="external">"Atrial fibrillation: Surgical ablation"</a>.)</p><p class="headingAnchor" id="H577201755"><span class="h1">INDICATIONS</span><span class="headingEndMark"> — </span>There are three settings in which a rhythm control strategy for the maintenance of sinus rhythm should be considered [<a href="#rid3">3</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Persistent symptoms (palpitations, dyspnea, lightheadedness, angina, syncope, and heart failure) despite adequate rate control.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An inability to attain adequate rate control (to prevent tachycardia-mediated cardiomyopathy). (See  <a class="medical medical_review" href="/z/d/html/1062.html" rel="external">"Arrhythmia-induced cardiomyopathy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patient preference. Some patients will strongly prefer to avoid either paroxysmal or persistent AF. </p><p></p><p>Maintenance antiarrhythmic drug therapy is <strong>not</strong> routinely used after cardioversion in patients with newly detected AF [<a href="#rid3">3</a>]. These issues are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/1045.html" rel="external">"Management of atrial fibrillation: Rhythm control versus rate control"</a>.) </p><p class="headingAnchor" id="H523850664"><span class="h1">INITIAL MANAGEMENT DECISIONS</span><span class="headingEndMark"> — </span>Prior to selecting and initiating antiarrhythmic drug therapy, the following issues should be considered.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rhythm versus rate control: </strong>The choice between a rhythm- or a rate-control strategy is determined by many factors, including patient age, the degree to which symptoms interfere with the quality of life, and concerns about antiarrhythmic drug therapy or catheter ablation. </p><p></p><p class="bulletIndent1">Our recommendations for the use of these two strategies are found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/1045.html" rel="external">"Management of atrial fibrillation: Rhythm control versus rate control", section on 'Summary and recommendations'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Precipitating factors:</strong> Before initiating a rhythm control strategy, any risk factors for atrial fibrillation (AF) should be addressed. Examples include hyperthyroidism, hypertension, heart failure, sleep apnea, and excess alcohol intake. (See  <a class="medical medical_review" href="/z/d/html/1004.html" rel="external">"Epidemiology, risk factors, and prevention of atrial fibrillation"</a> and  <a class="medical medical_review" href="/z/d/html/1004.html" rel="external">"Epidemiology, risk factors, and prevention of atrial fibrillation", section on 'Chronic disease associations'</a>.)</p><p></p><p class="bulletIndent1">Maintenance antiarrhythmic drug therapy may not be necessary after cardioversion in a patient with a transient or reversible cause (such as cardiac surgery, pericarditis, or pulmonary embolism). An option in such patients is beta blocker therapy after restoration of sinus rhythm, which may provide modest protection against recurrent AF [<a href="#rid4">4</a>]. However, short-term antiarrhythmic therapy can be considered in this situation as the underlying cause is treated in patients who are highly symptomatic.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anticoagulation: </strong>The proper use of anticoagulation in the period surrounding conversion to sinus rhythm is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/906.html" rel="external">"Prevention of embolization prior to and after restoration of sinus rhythm in atrial fibrillation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rate control: </strong>An atrioventricular (AV) nodal blocker, such as a beta blocker or a rate-slowing calcium channel blocker, is usually started before, or simultaneously with, antiarrhythmic drug therapy in patients who have demonstrated a moderate to rapid ventricular rate (≥110 beats per minute) during AF. Slowing of the rate generally improves symptoms prior to the restoration of sinus rhythm. This therapy is continued while the patient is in sinus rhythm to protect against a rapid ventricular rate should AF recur. This issue is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/938.html" rel="external">"Control of ventricular rate in patients with atrial fibrillation who do not have heart failure: Pharmacologic therapy", section on 'Evaluation and goal ventricular rate'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Restoration of sinus rhythm: </strong>Many patients with AF in whom a rhythm control strategy is chosen will need sinus rhythm restored prior to the initiation of long-term antiarrhythmic drug therapy. The restoration of sinus rhythm is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/1025.html" rel="external">"Atrial fibrillation: Cardioversion"</a>.)</p><p></p><p>Some patients with relatively infrequent episodes of paroxysmal atrial fibrillation can be managed with antiarrhythmic therapy given only at the time of the episode. This form of outpatient "pill-in-the-pocket" therapy for recurrent AF is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1025.html" rel="external">"Atrial fibrillation: Cardioversion", section on 'Pharmacologic cardioversion'</a>.)</p><p class="headingAnchor" id="H523850628"><span class="h1">SELECTING AN ANTIARRHYTHMIC DRUG</span><span class="headingEndMark"> — </span>Once the issues discussed above have been addressed, an antiarrhythmic agent can be chosen. The choice of drug is significantly influenced both by drug and patient characteristics. As with all therapeutic interventions, the choice of agent should take into account the benefit to risk ratio of the therapy chosen. (See <a class="local">'Proarrhythmia'</a> below.)</p><p><a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">Amiodarone</a>, <a class="drug drug_general" data-topicid="8904" href="/z/d/drug information/8904.html" rel="external">dofetilide</a>, <a class="drug drug_general" data-topicid="8449" href="/z/d/drug information/8449.html" rel="external">flecainide</a>, <a class="drug drug_general" data-topicid="9821" href="/z/d/drug information/9821.html" rel="external">propafenone</a>, <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">sotalol</a>, and less commonly <a class="drug drug_general" data-topicid="9037" href="/z/d/drug information/9037.html" rel="external">dronedarone</a> are the drugs we recommend to maintain sinus rhythm. (See <a class="local">'Concerns about dronedarone'</a> below.)</p><p>For additional information regarding the therapeutic use of these drugs, including information regarding dosing and side effects, the reader is referred to individual UpToDate topics on these drugs or to the individual drug monographs in our drug database.</p><p>The following points regarding antiarrhythmic drugs should be kept in mind in choosing therapy:</p><p class="bulletIndent1"><span class="glyph">●</span>Compared to other agents, <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a> is associated with the greatest likelihood of maintaining sinus rhythm, but also with the highest risk of long-term complications [<a href="#rid5">5,6</a>]. In addition, a 2014 report raises the possibility that amiodarone use in patients taking <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> is associated with an increased risk of stroke compared to those not taking the drug [<a href="#rid7">7</a>]. In this study, there was a lower time in the therapeutic range (of the international normalized ratio) in patients receiving amiodarone. (See  <a class="medical medical_review" href="/z/d/html/1038.html" rel="external">"Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Clinical trials"</a> and  <a class="medical medical_review" href="/z/d/html/931.html" rel="external">"Amiodarone: Adverse effects, potential toxicities, and approach to monitoring"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9846" href="/z/d/drug information/9846.html" rel="external">Quinidine</a>, <a class="drug drug_general" data-topicid="9813" href="/z/d/drug information/9813.html" rel="external">procainamide</a>, and <a class="drug drug_general" data-topicid="9378" href="/z/d/drug information/9378.html" rel="external">disopyramide</a> are no longer recommended for patients with AF, except perhaps in patients with vagally mediated atrial fibrillation (AF), as there are more effective drugs and due to extracardiac side effects as well as the concern about proarrhythmia [<a href="#rid8">8</a>]. (See <a class="local">'Proarrhythmia'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beta blockers are modestly effective in maintaining sinus rhythm and can be tried first in selected patients, such as those without structural heart disease who are concerned about proarrhythmia [<a href="#rid4">4,9,10</a>]. Of course beta blockers may have already been initiated to slow the ventricular rate in AF. (See <a class="local">'Proarrhythmia'</a> below and  <a class="medical medical_review" href="/z/d/html/1038.html" rel="external">"Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Clinical trials", section on 'Beta blockers'</a>.)</p><p></p><p>The following patient characteristics may influence decision making:</p><p class="bulletIndent1"><span class="glyph">●</span>The clinical features of the patient, such as presence or absence of clinical heart disease. We believe it is prudent to obtain a two-dimensional echocardiogram to screen for structural heart disease (eg, left ventricular systolic dysfunction, left ventricular hypertrophy, or valvular heart disease). An exercise or nuclear stress imaging test may be used to screen for coronary heart disease and is typically done before starting a class IC agent. (See <a class="local">'Atrial fibrillation without structural heart disease'</a> below and <a class="local">'Atrial fibrillation associated with structural heart disease'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The presence of paroxysmal compared to persistent AF [<a href="#rid1">1,11</a>]. As examples, our experts rarely use <a class="drug drug_general" data-topicid="8904" href="/z/d/drug information/8904.html" rel="external">dofetilide</a> for paroxysmal AF and infrequently choose <a class="drug drug_general" data-topicid="9037" href="/z/d/drug information/9037.html" rel="external">dronedarone</a> for persistent AF due to reduced efficacy compared with <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a>. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The presence of vagally-mediated AF [<a href="#rid12">12,13</a>]. The 2016 European Society of Cardiology AF guideline suggest that, because of its long-lasting anticholinergic activity, <a class="drug drug_general" data-topicid="9378" href="/z/d/drug information/9378.html" rel="external">disopyramide</a> may be considered in patients with vagally-induced AF (eg, occurring most often in athletic young men with slow heart rates during rest or sleep), as long as the patient does not have prostatism or glaucoma [<a href="#rid11">11,14</a>]. The combination of disopyramide and either a beta blocker or a calcium channel blocker must be used cautiously because of the additive negative inotropic effects. If disopyramide cannot be given or is not tolerated, <a class="drug drug_general" data-topicid="8449" href="/z/d/drug information/8449.html" rel="external">flecainide</a> and <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a> represent the sequential alternatives. Our experts use disopyramide cautiously due to concern for proarrhythmia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with adrenergically-mediated AF (eg, occurring during exercise or other activity), we suggest beta blockers as first-line therapy, followed by <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">sotalol</a> and <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a>. </p><p></p><p>Antiarrhythmic drugs are associated with a potential for serious adverse side effects, particularly the induction of proarrhythmia. Thus, they should be prescribed only by practitioners familiar with their use. Patients should be fully informed of both the benefits and risk associated with the use of these drugs. (See <a class="local">'Drug-related arrhythmias and mortality'</a> below.)</p><p>As the expectation of antiarrhythmic therapy is to reduce the frequency and duration of episodes, improve quality of life, and prevent hospitalization, a recurrence of AF does not necessarily denote a failure of the medication or mandate a change to a different antiarrhythmic drug. </p><p class="headingAnchor" id="H9"><span class="h2">Atrial fibrillation without structural heart disease</span><span class="headingEndMark"> — </span>Patients without structural heart disease include those with hypertension who do not have left ventricular hypertrophy. The author and reviewers of this topic generally select <a class="drug drug_general" data-topicid="8449" href="/z/d/drug information/8449.html" rel="external">flecainide</a> or <a class="drug drug_general" data-topicid="9821" href="/z/d/drug information/9821.html" rel="external">propafenone</a> as the first antiarrhythmic drug for these patients due to its relatively good side effect profile, efficacy, and ease of use. The use of these drugs in patients &gt;70 years of age should be considered more cautiously, given the higher likelihood of underlying coronary artery disease.</p><p>In these patients, <a class="drug drug_general" data-topicid="8449" href="/z/d/drug information/8449.html" rel="external">flecainide</a>, <a class="drug drug_general" data-topicid="9821" href="/z/d/drug information/9821.html" rel="external">propafenone</a>, <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a>, <a class="drug drug_general" data-topicid="9037" href="/z/d/drug information/9037.html" rel="external">dronedarone</a>, <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">sotalol</a>, and <a class="drug drug_general" data-topicid="8904" href="/z/d/drug information/8904.html" rel="external">dofetilide</a> are superior to placebo for maintaining sinus rhythm. (See  <a class="medical medical_review" href="/z/d/html/1038.html" rel="external">"Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Clinical trials"</a>.) </p><p>For those patients in whom <a class="drug drug_general" data-topicid="8449" href="/z/d/drug information/8449.html" rel="external">flecainide</a> or <a class="drug drug_general" data-topicid="9821" href="/z/d/drug information/9821.html" rel="external">propafenone</a> will not be used as the preferred agent, the following points can influence the choice of antiarrhythmic drug in patients without structural heart disease:</p><p class="bulletIndent1"><span class="glyph">●</span>In the Canadian Trial of Atrial fibrillation, AFFIRM, and the SAFE-T randomized trials, <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a> was more effective than <a class="drug drug_general" data-topicid="8449" href="/z/d/drug information/8449.html" rel="external">flecainide</a>, <a class="drug drug_general" data-topicid="9821" href="/z/d/drug information/9821.html" rel="external">propafenone</a>, or <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">sotalol</a> (which have nearly equivalent efficacy to each other), but has a significantly higher rate of adverse side effects. (See  <a class="medical medical_review" href="/z/d/html/1038.html" rel="external">"Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Clinical trials", section on 'Amiodarone'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a meta-analysis of trials where the effect of <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a> versus <a class="drug drug_general" data-topicid="9037" href="/z/d/drug information/9037.html" rel="external">dronedarone</a> was estimated with the use of indirect comparison and normal logistic meta-analysis models, amiodarone was found to be more effective in maintaining sinus rhythm, but at the expense of greater drug discontinuation secondary to adverse events [<a href="#rid15">15</a>]. (See  <a class="medical medical_review" href="/z/d/html/1038.html" rel="external">"Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Clinical trials", section on 'Dronedarone'</a>.) </p><p></p><p class="bulletIndent1">Both <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a> and <a class="drug drug_general" data-topicid="9037" href="/z/d/drug information/9037.html" rel="external">dronedarone</a> are associated with significant side effects. We suggest carefully discussing these with the patient prior to initiating therapy. (See  <a class="medical medical_review" href="/z/d/html/931.html" rel="external">"Amiodarone: Adverse effects, potential toxicities, and approach to monitoring"</a> and  <a class="medical medical_review" href="/z/d/html/16216.html" rel="external">"Clinical uses of dronedarone"</a>.)In the EMERALD trial, <a class="drug drug_general" data-topicid="8904" href="/z/d/drug information/8904.html" rel="external">Dofetilide</a> had a somewhat better efficacy than <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">sotalol</a>. (See  <a class="medical medical_review" href="/z/d/html/1038.html" rel="external">"Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Clinical trials", section on 'Dofetilide'</a>.)</p><p></p><p>Some cardiologists prefer to use low-dose <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a> (100 to 200 mg per day), particularly in older patients, in preference to <a class="drug drug_general" data-topicid="8449" href="/z/d/drug information/8449.html" rel="external">flecainide</a>, <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">sotalol</a>, or <a class="drug drug_general" data-topicid="9037" href="/z/d/drug information/9037.html" rel="external">dronedarone</a> for two principal reasons: greater efficacy than sotalol and dronedarone  (<a class="graphic graphic_figure graphicRef69285" href="/z/d/graphic/69285.html" rel="external">figure 1</a>) [<a href="#rid16">16-18</a>], and a very low incidence of torsades de pointes [<a href="#rid19">19,20</a>]. In addition, since amiodarone has beta blocking and calcium channel blocking activity, the ventricular rate is usually slower and better tolerated if AF does recur. If amiodarone is used for rhythm control, the need for additional medications to control rate (eg, beta blockers or calcium channel blockers) may be decreased. Despite these advantages, low-dose amiodarone still has appreciable toxicity, including thyroid disease, hepatic dysfunction, lung disease, neurologic abnormalities, and bradycardia [<a href="#rid19">19,20</a>]. (See  <a class="medical medical_review" href="/z/d/html/931.html" rel="external">"Amiodarone: Adverse effects, potential toxicities, and approach to monitoring"</a>.)</p><p class="headingAnchor" id="H10"><span class="h2">Atrial fibrillation associated with structural heart disease</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">Amiodarone</a>, <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">sotalol</a>, and <a class="drug drug_general" data-topicid="8904" href="/z/d/drug information/8904.html" rel="external">dofetilide</a> are the most commonly recommended first-line drugs in patients with structural heart disease  (<a class="graphic graphic_algorithm graphicRef95079" href="/z/d/graphic/95079.html" rel="external">algorithm 1</a>) [<a href="#rid11">11</a>]. Our authors and reviewers prefer either <a class="drug drug_general" data-topicid="9037" href="/z/d/drug information/9037.html" rel="external">dronedarone</a> or sotalol to amiodarone and dofetilide. Dronedarone is easier to use than sotalol (continuous monitoring of initiation required), but is less efficacious. (See  <a class="medical medical_review" href="/z/d/html/925.html" rel="external">"Clinical uses of sotalol"</a>.)</p><p>These drugs (with the exception of <a class="drug drug_general" data-topicid="9037" href="/z/d/drug information/9037.html" rel="external">dronedarone</a>) were used for initial therapy in almost 70 percent of patients in AFFIRM, 88 percent of whom had organic heart disease and/or hypertension [<a href="#rid21">21</a>]. <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">Amiodarone</a> was significantly more effective than <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">sotalol</a> in the CTAF, AFFIRM, and SAFE-T trials [<a href="#rid16">16-18</a>]. However, in SAFE-T, sotalol was as effective as amiodarone in the subgroup of patients with coronary heart disease [<a href="#rid17">17</a>]. (See  <a class="medical medical_review" href="/z/d/html/1038.html" rel="external">"Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Clinical trials"</a>.)</p><p class="headingAnchor" id="H11"><span class="h3">Coronary heart disease</span><span class="headingEndMark"> — </span>In patients with coronary heart disease who do not have heart failure, <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">sotalol</a>, <a class="drug drug_general" data-topicid="9037" href="/z/d/drug information/9037.html" rel="external">dronedarone</a>, <a class="drug drug_general" data-topicid="8904" href="/z/d/drug information/8904.html" rel="external">dofetilide</a>, and <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a> are acceptable choices  (<a class="graphic graphic_table graphicRef66133" href="/z/d/graphic/66133.html" rel="external">table 1</a> and <a class="graphic graphic_algorithm graphicRef95079" href="/z/d/graphic/95079.html" rel="external">algorithm 1</a>) [<a href="#rid11">11,22,23</a>]. We prefer sotalol due to its better extracardiac side effect profiles. <a class="drug drug_general" data-topicid="8449" href="/z/d/drug information/8449.html" rel="external">Flecainide</a> and <a class="drug drug_general" data-topicid="9821" href="/z/d/drug information/9821.html" rel="external">propafenone</a> are contraindicated in this population. (See  <a class="medical medical_review" href="/z/d/html/1038.html" rel="external">"Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Clinical trials"</a> and  <a class="medical medical_review" href="/z/d/html/86747.html" rel="external">"Major side effects of class I antiarrhythmic drugs"</a>.)</p><p>In the Cardiac Arrhythmia Suppression Trial (CAST) of patients with drug-suppressible ventricular premature beats in the year following a myocardial infarction, <a class="drug drug_general" data-topicid="8449" href="/z/d/drug information/8449.html" rel="external">flecainide</a> increased mortality compared to placebo  (<a class="graphic graphic_figure graphicRef59975" href="/z/d/graphic/59975.html" rel="external">figure 2</a>) [<a href="#rid24">24</a>]. Although <a class="drug drug_general" data-topicid="9821" href="/z/d/drug information/9821.html" rel="external">propafenone</a> was not used in CAST and may not have the same potential for proarrhythmia as flecainide and encainide [<a href="#rid25">25</a>], it cannot be recommended in patients with underlying heart disease [<a href="#rid26">26</a>]. </p><p>The extension of this concern to structural heart disease other than coronary artery disease stems in part from the <a class="drug drug_general" data-topicid="8449" href="/z/d/drug information/8449.html" rel="external">flecainide</a> clinical and safety database, which was used in a retrospective study demonstrating that the presence of structural heart disease including valvular heart disease, congenital heart disease, and cardiomyopathies lead to an alarming increase in proarrhythmia and death [<a href="#rid27">27</a>]. </p><p class="headingAnchor" id="H12"><span class="h3">Heart failure</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">Amiodarone</a> and <a class="drug drug_general" data-topicid="8904" href="/z/d/drug information/8904.html" rel="external">dofetilide</a>, are used in patients with AF and heart failure (HF) or those with a left ventricular ejection fraction less than 35 percent. Our authors and reviewers are more comfortable using dofetilide in this setting with an implantable defibrillator in place or in younger patients with less severe impairment of left ventricular systolic function. This issue is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/977.html" rel="external">"The management of atrial fibrillation in patients with heart failure"</a>.)</p><p><a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">Sotalol</a>, <a class="drug drug_general" data-topicid="9821" href="/z/d/drug information/9821.html" rel="external">propafenone</a>, <a class="drug drug_general" data-topicid="9037" href="/z/d/drug information/9037.html" rel="external">dronedarone</a>, and <a class="drug drug_general" data-topicid="8449" href="/z/d/drug information/8449.html" rel="external">flecainide</a> should not be used in patients with heart failure, due to studies showing an increase in mortality with these agents. (See  <a class="medical medical_review" href="/z/d/html/925.html" rel="external">"Clinical uses of sotalol"</a> and  <a class="medical medical_review" href="/z/d/html/926.html" rel="external">"Amiodarone: Clinical uses"</a> and  <a class="medical medical_review" href="/z/d/html/86747.html" rel="external">"Major side effects of class I antiarrhythmic drugs"</a>.)</p><p class="headingAnchor" id="H13"><span class="h3">Left ventricular hypertrophy</span><span class="headingEndMark"> — </span>Patients with significant left ventricular hypertrophy (defined as left ventricular wall thickness greater 1.4 cm for the purposes of this discussion) due to hypertension, hypertrophic cardiomyopathy, or aortic stenosis have underlying subendocardial ischemia and electrophysiologic abnormalities. These increase the risk for proarrhythmia with antiarrhythmic agents. (See  <a class="medical medical_review" href="/z/d/html/966.html" rel="external">"Left ventricular hypertrophy and arrhythmia"</a> and <a class="local">'Proarrhythmia'</a> below and  <a class="medical medical_review" href="/z/d/html/2112.html" rel="external">"Left ventricular hypertrophy: Clinical findings and ECG diagnosis"</a>.)</p><p><a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">Sotalol</a>, <a class="drug drug_general" data-topicid="8449" href="/z/d/drug information/8449.html" rel="external">flecainide</a> and <a class="drug drug_general" data-topicid="9821" href="/z/d/drug information/9821.html" rel="external">propafenone</a> are thought to have a significant arrhythmic risk in patients with left ventricular hypertrophy (LVH). <a class="drug drug_general" data-topicid="9037" href="/z/d/drug information/9037.html" rel="external">Dronedarone</a> has been evaluated in patients with LVH and is thought to be relatively safe [<a href="#rid23">23</a>], although our experts rarely use it. <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">Amiodarone</a> is another therapeutic option. (See  <a class="medical medical_review" href="/z/d/html/16216.html" rel="external">"Clinical uses of dronedarone"</a>.)</p><p class="headingAnchor" id="H16"><span class="h2">Drug-resistant atrial fibrillation</span><span class="headingEndMark"> — </span>Some patients are refractory to individual antiarrhythmic agents plus an AV nodal blocker or develop side effects on doses necessary for arrhythmia prevention. Although some have suggested that combination antiarrhythmic drug therapy (eg, a class IC agent with <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">sotalol</a> or <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a>, often in lower doses, or the combination of <a class="drug drug_general" data-topicid="9037" href="/z/d/drug information/9037.html" rel="external">dronedarone</a> plus <a class="drug drug_general" data-topicid="10262" href="/z/d/drug information/10262.html" rel="external">ranolazine</a>) may be an alternative, there are limited data to support such an approach and the patient may be exposed to a greater risk of proarrhythmia and other side effects [<a href="#rid28">28</a>]. </p><p>As a result, combination antiarrhythmic drug therapy is not recommended. Such patients can be treated with a rate control strategy or referred for nonpharmacologic therapy to prevent recurrent AF including surgery (such as the maze operation) or catheter ablation (such as pulmonary vein isolation). (See  <a class="medical medical_review" href="/z/d/html/949.html" rel="external">"Atrial fibrillation: Catheter ablation"</a> and  <a class="medical medical_review" href="/z/d/html/1044.html" rel="external">"The role of pacemakers in the prevention of atrial fibrillation"</a> and  <a class="medical medical_review" href="/z/d/html/1046.html" rel="external">"Atrial fibrillation: Surgical ablation"</a>.)</p><p class="headingAnchor" id="H425527372"><span class="h1">INPATIENT VERSUS OUTPATIENT INITIATION</span><span class="headingEndMark"> — </span>Many patients begun on antiarrhythmic drug therapy should be hospitalized for continuous electrocardiographic monitoring due to a 10 to 15 percent incidence of adverse cardiac events during the initiation of therapy [<a href="#rid29">29</a>]. (See <a class="local">'Proarrhythmia'</a> below and  <a class="medical medical_review" href="/z/d/html/961.html" rel="external">"Arrhythmia management for the primary care clinician", section on 'Antiarrhythmic drugs'</a>.)</p><p>The two complications of greatest concern are bradycardia and proarrhythmia. Other adverse cardiac events can include significant QT prolongation, heart failure, rapid ventricular rate, conduction abnormalities, hypotension, and stroke. The risk is greatest in the first 24 hours and in patients with a prior myocardial infarction. </p><p>Outpatient initiation of antiarrhythmic drug therapy with the following agents may be considered:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8449" href="/z/d/drug information/8449.html" rel="external">Flecainide</a> or <a class="drug drug_general" data-topicid="9821" href="/z/d/drug information/9821.html" rel="external">propafenone</a> in patients in sinus rhythm who have no underlying structural heart disease, normal baseline QT intervals, and no profound bradycardia or suspected sinus or atrioventricular (AV) node dysfunction [<a href="#rid11">11</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">Amiodarone</a> or <a class="drug drug_general" data-topicid="9037" href="/z/d/drug information/9037.html" rel="external">dronedarone</a> in selected patients who have no other risk factors for torsades de pointes (eg, hypokalemia, hypomagnesemia), sinus node dysfunction, or AV conduction disease. Dronedarone and amiodarone are the only two drugs that can be initiated in outpatients while in atrial fibrillation.</p><p></p><p>Patients with an implantable cardioverter-defibrillator (ICD) represent another group in which outpatient initiation of therapy can be tried, since the ICD provides protection against the risks associated with bradyarrhythmias and tachyarrhythmias. However, one should be cognizant of the potential effects of antiarrhythmic drugs on ventricular defibrillation threshold and ventricular tachycardia cycle length, which could influence the efficacy of ICD therapy.</p><p>The initiation of antiarrhythmic drugs in patients with paroxysmal AF while they are in sinus rhythm is also associated with some risk. In a review of 409 outpatient initiation trials for a history of recurrent AF or atrial flutter, adverse cardiac events occurred in 17 (4.5 percent); these included three deaths, three permanent pacemakers for bradycardia, and 11 dose reductions for bradycardia [<a href="#rid30">30</a>].</p><p>Inpatient initiation with continuous telemetry of higher-risk drugs such as <a class="drug drug_general" data-topicid="8904" href="/z/d/drug information/8904.html" rel="external">dofetilide</a> and <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">sotalol</a> is typically done over a course of three days, which encompasses five half-lives allowing for achievement of steady-state plasma concentrations. In highly selected patients (eg, normal renal function, no bradycardia, and normal QT interval), sotalol can be loaded as outpatient with event monitor and closely following electrocardiogram for QT interval while in sinus rhythm.</p><p class="headingAnchor" id="H523854472"><span class="h1">LONG-TERM ISSUES</span></p><p class="headingAnchor" id="H577202428"><span class="h2">AF recurrence</span><span class="headingEndMark"> — </span>Recurrent atrial fibrillation (AF) should not necessarily be labeled as treatment failure. Some patients will elect to continue drug therapy (and, in some cases, occasional cardioversion) because the arrhythmia burden has been substantially reduced as evidenced by episodes that are less frequent, shorter, or associated with milder symptoms. Nonpharmacologic therapies are another option in such patients. (See  <a class="medical medical_review" href="/z/d/html/1012.html" rel="external">"Atrial fibrillation: Atrioventricular node ablation"</a> and  <a class="medical medical_review" href="/z/d/html/949.html" rel="external">"Atrial fibrillation: Catheter ablation"</a>.)</p><p>If a patient has unacceptable recurrent AF on one antiarrhythmic drug, the drug is discontinued and another (and on rare occasion a third) agent is tried. </p><p class="headingAnchor" id="H523854907"><span class="h2">Dosing</span><span class="headingEndMark"> — </span>The starting and maintenance doses for <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a>, <a class="drug drug_general" data-topicid="9037" href="/z/d/drug information/9037.html" rel="external">dronedarone</a>, <a class="drug drug_general" data-topicid="9821" href="/z/d/drug information/9821.html" rel="external">propafenone</a>, <a class="drug drug_general" data-topicid="8449" href="/z/d/drug information/8449.html" rel="external">flecainide</a>, <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">sotalol</a>, <a class="drug drug_general" data-topicid="9378" href="/z/d/drug information/9378.html" rel="external">disopyramide</a>, and <a class="drug drug_general" data-topicid="8904" href="/z/d/drug information/8904.html" rel="external">dofetilide</a> are found in the <a class="external" href="/drug-interactions">drug interactions program</a> available in UpToDate. Many factors including age, sex, weight, renal or hepatic function, and characteristics on the electrocardiogram influence the starting dose for many of these. (See  <a class="medical medical_review" href="/z/d/html/1038.html" rel="external">"Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Clinical trials"</a>.)</p><p class="headingAnchor" id="H523855015"><span class="h2">Drug-related arrhythmias and mortality</span><span class="headingEndMark"> — </span>The use of antiarrhythmic drugs is associated with possible life-threatening side effects. The greatest concerns with these agents are proarrhythmia (and consequent tachyarrhythmia) and bradycardia. Patients should be instructed to report symptoms suggestive of the development of drug related arrhythmias, such as syncope, lightheadedness or dizzy spells, or worsening exercise intolerance. (See  <a class="medical medical_review" href="/z/d/html/961.html" rel="external">"Arrhythmia management for the primary care clinician", section on 'Antiarrhythmic drugs'</a> and  <a class="medical medical_review" href="/z/d/html/961.html" rel="external">"Arrhythmia management for the primary care clinician", section on 'Symptoms'</a>.)</p><p>A 2012 meta-analysis of 56 studies (20,771 patients) compared one or more antiarrhythmic drugs to control or to each other [<a href="#rid31">31</a>]. Compared to controls, the use of the class IA antiarrhythmics <a class="drug drug_general" data-topicid="9846" href="/z/d/drug information/9846.html" rel="external">quinidine</a> and <a class="drug drug_general" data-topicid="9378" href="/z/d/drug information/9378.html" rel="external">disopyramide</a> (odds ratio 2.39, 95% CI 1.03-5.59) or <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">sotalol</a> (2.47, 95% CI 1.2-5.05) was associated with increased all-cause mortality, whereas the use of <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a>, <a class="drug drug_general" data-topicid="9037" href="/z/d/drug information/9037.html" rel="external">dronedarone</a>, and <a class="drug drug_general" data-topicid="8904" href="/z/d/drug information/8904.html" rel="external">dofetilide</a> was not (odds ratios were not calculated for <a class="drug drug_general" data-topicid="8449" href="/z/d/drug information/8449.html" rel="external">flecainide</a> or <a class="drug drug_general" data-topicid="9821" href="/z/d/drug information/9821.html" rel="external">propafenone</a>). All antiarrhythmics studied showed increased pro-arrhythmic effects (counting both bradyarrhythmias and tachyarrhythmias attributable to treatment), with the exceptions of amiodarone, dronedarone, and propafenone.</p><p class="headingAnchor" id="H523855022"><span class="h3">Proarrhythmia</span><span class="headingEndMark"> — </span>All of the antiarrhythmic drugs used to maintain sinus rhythm have the potential to increase ectopy or induce or aggravate monomorphic ventricular tachycardia (VT), torsades de pointes, or ventricular fibrillation (VF); this is referred to as proarrhythmia  (<a class="graphic graphic_table graphicRef66133" href="/z/d/graphic/66133.html" rel="external">table 1</a>). </p><p>In addition to its baseline potential to predispose the patient to proarrhythmia, a drug that is initially safe may become proarrhythmic when the patient develops coronary heart disease or heart failure or is treated with other medications that in combination may be arrhythmogenic. Thus, the patient should be alerted to the potential significance of symptoms such as syncope and dyspnea and warned about the use of noncardiac drugs that can prolong the QT interval  (<a class="graphic graphic_table graphicRef57431" href="/z/d/graphic/57431.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/z/d/html/1043.html" rel="external">"Acquired long QT syndrome: Definitions, pathophysiology, and causes"</a>.)</p><p>We agree with the following recommendations made according to drug class in the American College of Cardiology/American Heart Association/European Society of Cardiology guideline [<a href="#rid11">11</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>With type IC drugs, QRS widening should not be permitted to exceed 150 percent of the baseline QRS duration. Exercise testing may detect QRS widening that occurs only at rapid heart rates (use-dependent conduction slowing). Exercise testing is also a useful way to screen for exercise-induced proarrhythmia and is typically performed one to two weeks after drug initiation. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For type IA or type III drugs  (<a class="graphic graphic_table graphicRef120433" href="/z/d/graphic/120433.html" rel="external">table 3</a>), with the possible exception of <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a>, the corrected QT interval in sinus rhythm should remain below 520 milliseconds. More specific and conservative recommendations are available for <a class="drug drug_general" data-topicid="8904" href="/z/d/drug information/8904.html" rel="external">dofetilide</a> in the package insert.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>During follow-up, serum creatinine, potassium, and magnesium concentrations should be monitored periodically because proarrhythmia is increased by renal insufficiency, which can lead to drug accumulation, hyperkalemia, and hypermagnesemia. The presence of renal insufficiency warrants dose reduction or cessation of <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">sotalol</a> and <a class="drug drug_general" data-topicid="8904" href="/z/d/drug information/8904.html" rel="external">dofetilide</a>. In comparison, <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a> is metabolized in the liver and dose adjustment is probably necessary in patients with hepatic dysfunction. (See  <a class="medical medical_review" href="/z/d/html/931.html" rel="external">"Amiodarone: Adverse effects, potential toxicities, and approach to monitoring", section on 'Adverse hepatic effects'</a>.)</p><p></p><p class="headingAnchor" id="H523855029"><span class="h3">Bradyarrhythmia</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">Amiodarone</a> and <a class="drug drug_general" data-topicid="9037" href="/z/d/drug information/9037.html" rel="external">dronedarone</a> can cause both sinus bradycardia and AV nodal block, with an overall incidence of bradycardic events of about 5 percent. <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">Sotalol</a>, like other beta blockers, can also cause bradycardia. In some cases, permanent pacemaker placement is necessary to permit continued use of these agents. (See  <a class="medical medical_review" href="/z/d/html/931.html" rel="external">"Amiodarone: Adverse effects, potential toxicities, and approach to monitoring"</a> and  <a class="medical medical_review" href="/z/d/html/925.html" rel="external">"Clinical uses of sotalol"</a>.)</p><p class="headingAnchor" id="H519908970"><span class="h3">Ambulatory monitoring</span><span class="headingEndMark"> — </span>Our authors and reviewers have differing thresholds for the use of ambulatory monitoring to screen for proarrhythmia and bradycardia, ranging from screening in the highest risk cases only to screening in everyone. Some experts suggest screening all patients with an ambulatory event monitor for at least two weeks after initiation of therapy, looking for QT interval prolongation or bradyarrhythmias. The basis for this recommendation is that many events occur after three days [<a href="#rid30">30</a>]. For those experts who are more selective based on patient risk, high-risk is defined as baseline bradycardia or borderline QT prolongation, heart failure, or systolic left ventricular dysfunction. Others perform routine monitoring when <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">sotalol</a>, <a class="drug drug_general" data-topicid="8449" href="/z/d/drug information/8449.html" rel="external">flecainide</a>, or <a class="drug drug_general" data-topicid="9821" href="/z/d/drug information/9821.html" rel="external">propafenone</a> are chosen. <a class="drug drug_general" data-topicid="8904" href="/z/d/drug information/8904.html" rel="external">Dofetilide</a> must be initiated in a setting with continuous monitoring. (See  <a class="medical medical_review" href="/z/d/html/1033.html" rel="external">"Clinical use of dofetilide"</a>.)</p><p>For those patients who are not referred for ambulatory monitoring, we suggest that a 12-lead electrocardiogram be obtained after the initiation of antiarrhythmic drug therapy.</p><p class="headingAnchor" id="H266072426"><span class="h2">Short- versus long-term therapy</span><span class="headingEndMark"> — </span>Based on concerns about drug related arrhythmias and the observation that the atrial action potential normalizes after two to four weeks of sinus rhythm (after AF), the concept that short-term therapy might be as effective and safer than long-term therapy has been proposed. This concept was tested in the Flec-SL non-inferiority trial, which randomly assigned 554 patients with persistent AF and who were intended to undergo cardioversion to either four weeks or six months of <a class="drug drug_general" data-topicid="8449" href="/z/d/drug information/8449.html" rel="external">flecainide</a> (200 to 300 mg per day) [<a href="#rid32">32</a>]. All patients had successful restoration of sinus rhythm and were then followed with daily telemetric electrocardiography (and Holter monitoring whenever AF was noted on two ECGs) for six months. </p><p>The primary outcome of time to persistent AF or death occurred in 46 and 39 percent of patients, respectively, which did not meet the criteria of non-inferiority. In addition, a post-hoc analysis of patients who had not reached the primary endpoint in the first month found long-term therapy to be superior (Kaplan-Meier estimate of difference 14.3 percent; hazard ratio 0.3; p = 0.0001). We do not consider short-term therapy appropriate for most patients with persistent AF. </p><p class="headingAnchor" id="H58992353"><span class="h2">Concerns about dronedarone</span><span class="headingEndMark"> — </span>Patients with severe heart failure (HF) (generally those with NYHA class III or IV HF, or those who have been hospitalized with HF in the past four weeks) or those with an ejection fraction of &lt;35 percent should not receive <a class="drug drug_general" data-topicid="9037" href="/z/d/drug information/9037.html" rel="external">dronedarone</a>. (See  <a class="medical medical_review" href="/z/d/html/977.html" rel="external">"The management of atrial fibrillation in patients with heart failure", section on 'Antiarrhythmic drugs'</a>.)</p><p>The Permanent Atrial fibriLLAtion outcome Study (PALLAS) was designed to test the hypothesis that <a class="drug drug_general" data-topicid="9037" href="/z/d/drug information/9037.html" rel="external">dronedarone</a> would improve major outcomes in 10,000 patients with permanent AF, over 70 percent of whom had New York Heart Association heart failure class I to III or left ventricular systolic dysfunction at baseline. The rationale was that patients with permanent AF, which affects up to 50 percent of patients with AF, have an increased risk of adverse cardiovascular outcomes including death and myocardial infarction as well as systemic embolization. The ATHENA trial showed a significant reduction in cardiovascular events with dronedarone in patients with paroxysmal or persistent AF. (See  <a class="medical medical_review" href="/z/d/html/1038.html" rel="external">"Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Clinical trials", section on 'Dronedarone'</a>.)</p><p>Patients in PALLAS were treated with standard therapies for AF and then randomly assigned to <a class="drug drug_general" data-topicid="9037" href="/z/d/drug information/9037.html" rel="external">dronedarone</a> or placebo. The study was stopped early (3236 patients enrolled), after a significantly increased risk (Hazard Ratio 2.29, 95% CI 1.34-3.94) of cardiovascular events (cardiovascular death, myocardial infarction, stroke and systemic embolism) was observed in the dronedarone arm [<a href="#rid33">33</a>]. The individual secondary end points of stroke, death from cardiovascular causes, and hospitalization for heart failure were also significantly increased in the dronedarone group. (See <a class="local">'Summary and recommendations'</a> below.)</p><p>The European Medicines Agency and the United States Food and Drug Agency (USFDA) have advised against the use of <a class="drug drug_general" data-topicid="9037" href="/z/d/drug information/9037.html" rel="external">dronedarone</a> in patients with permanent AF [<a href="#rid34">34,35</a>]. In addition, the USFDA now recommends that people taking the drug should have an electrocardiogram every three months to make sure that AF has not become permanent. For patients taking dronedarone, routine monitoring of lung and liver function is not mandated by the USFDA; however, periodic monitoring may be reasonable [<a href="#rid36">36</a>]. (See  <a class="medical medical_review" href="/z/d/html/16216.html" rel="external">"Clinical uses of dronedarone", section on 'Maintenance of sinus rhythm'</a>.)</p><p class="headingAnchor" id="H418068878"><span class="h2">Follow-up</span><span class="headingEndMark"> — </span>We consider the following approach to follow-up reasonable:</p><p class="bulletIndent1"><span class="glyph">●</span>We perform an ECG one week after initiation of any antiarrhythmic drug. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We typically see patients within three months of initiating a new antiarrhythmic drug to assess efficacy and side effects. This is in addition to commonly performing ambulatory monitoring after drug initiation. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients are typically seen every 6 to 12 months unless there are particular concerns regarding QT interval prolongation, bradycardia, or other issues identified on the ECG.</p><p></p><p>Specific follow-up recommendations for individual drugs are presented separately. (See  <a class="medical medical_review" href="/z/d/html/931.html" rel="external">"Amiodarone: Adverse effects, potential toxicities, and approach to monitoring"</a> and  <a class="medical medical_review" href="/z/d/html/925.html" rel="external">"Clinical uses of sotalol", section on 'Major side effects'</a> and  <a class="medical medical_review" href="/z/d/html/1033.html" rel="external">"Clinical use of dofetilide", section on 'Safety'</a> and  <a class="medical medical_review" href="/z/d/html/86747.html" rel="external">"Major side effects of class I antiarrhythmic drugs", section on 'Flecainide'</a> and  <a class="medical medical_review" href="/z/d/html/86747.html" rel="external">"Major side effects of class I antiarrhythmic drugs", section on 'Propafenone'</a>.)</p><p class="headingAnchor" id="H523850780"><span class="h1">RECOMMENDATIONS OF OTHERS</span><span class="headingEndMark"> — </span>Our recommendations for the use of antiarrhythmic drugs to maintain sinus rhythm in patients with AF are generally in agreement with recommendations from the American Heart Association/American College of Cardiology/Heart Rhythm Society (2014) and its 2019 focused update, as well as the European Society of Cardiology (2016) [<a href="#rid13">13,37-39</a>]. (See <a class="local">'Summary and recommendations'</a> below.)</p><p class="headingAnchor" id="H3495664257"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/112091.html" rel="external">"Society guideline links: Atrial fibrillation"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/112260.html" rel="external">"Society guideline links: Arrhythmias in adults"</a>.)</p><p class="headingAnchor" id="H285342968"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, “The Basics” and “Beyond the Basics.” The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on “patient info” and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/16237.html" rel="external">"Patient education: Medicines for atrial fibrillation (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H5304343"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial management decisions </strong>– For those patients with atrial fibrillation (AF) in whom a rhythm-control strategy is chosen, the principal goal is to reduce symptoms by decreasing the frequency and duration of episodes [<a href="#rid1">1,2</a>]. (See <a class="local">'Initial management decisions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Selecting an antiarrhythmic drug</strong> – (See <a class="local">'Selecting an antiarrhythmic drug'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Beta blockers are modestly effective in maintaining sinus rhythm and can be tried first in selected patients, such as those without structural heart disease who are concerned about proarrhythmia. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Compared to placebo, <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a>, <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">sotalol</a>, <a class="drug drug_general" data-topicid="8904" href="/z/d/drug information/8904.html" rel="external">dofetilide</a>, <a class="drug drug_general" data-topicid="9037" href="/z/d/drug information/9037.html" rel="external">dronedarone</a>, <a class="drug drug_general" data-topicid="8449" href="/z/d/drug information/8449.html" rel="external">flecainide</a>, and <a class="drug drug_general" data-topicid="9821" href="/z/d/drug information/9821.html" rel="external">propafenone</a> are effective for the maintenance of sinus rhythm, but maintenance rates at one year are significantly less than 75 percent. Amiodarone is consistently more effective than the other antiarrhythmic drugs.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drug-related arrhythmias and mortality </strong>–<strong> </strong>In addition to less-than-optimal efficacy, serious drug-related adverse side effects limit the use of these drugs. Antiarrhythmic drug therapy should be prescribed only by practitioners familiar with their use. Patients should be fully informed of both the benefits and risks associated with the use of these drugs. (See <a class="local">'Drug-related arrhythmias and mortality'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inpatient versus outpatient initiation </strong>– Based upon the potential for drug toxicity in the form of induced bradycardia or tachycardia, many patients will need to be hospitalized for continuous electrocardiographic monitoring. <a class="drug drug_general" data-topicid="8904" href="/z/d/drug information/8904.html" rel="external">Dofetilide</a> must be initiated in a setting with continuous monitoring. (See <a class="local">'Inpatient versus outpatient initiation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Selecting an antiarrhythmic drug</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Atrial fibrillation without structural heart disease </strong>– For patients with no structural heart disease and no apparent risk for drug-induced bradycardia or tachycardia, we suggest <a class="drug drug_general" data-topicid="8449" href="/z/d/drug information/8449.html" rel="external">flecainide</a> or <a class="drug drug_general" data-topicid="9821" href="/z/d/drug information/9821.html" rel="external">propafenone</a> as the preferred antiarrhythmic drug (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">Amiodarone</a>, <a class="drug drug_general" data-topicid="8904" href="/z/d/drug information/8904.html" rel="external">dofetilide</a>, <a class="drug drug_general" data-topicid="9037" href="/z/d/drug information/9037.html" rel="external">dronedarone</a>, or <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">sotalol</a> may be used, with sotalol chosen more often by our authors and reviewers. Practitioners should choose only those agents with which they have significant familiarity. (See <a class="local">'Atrial fibrillation without structural heart disease'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Coronary heart disease </strong>– For patients with coronary artery disease who do not have advanced heart failure, we suggest <a class="drug drug_general" data-topicid="9037" href="/z/d/drug information/9037.html" rel="external">dronedarone</a> or <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">sotalol</a> in preference to <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a> (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). Amiodarone is a reasonable choice in patients who prefer its greater efficacy despite its worse extracardiac side-effect profile. (See <a class="local">'Coronary heart disease'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Heart failure </strong>– For patients with heart failure, we suggest <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a> in preference to <a class="drug drug_general" data-topicid="8904" href="/z/d/drug information/8904.html" rel="external">dofetilide</a> (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). <a class="drug drug_general" data-topicid="8449" href="/z/d/drug information/8449.html" rel="external">Flecainide</a>, <a class="drug drug_general" data-topicid="9821" href="/z/d/drug information/9821.html" rel="external">propafenone</a>, <a class="drug drug_general" data-topicid="9037" href="/z/d/drug information/9037.html" rel="external">dronedarone</a>, and <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">sotalol</a> are contraindicated in these patients. (See <a class="local">'Heart failure'</a> above.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Left ventricular hypertrophy </strong>– For patients with left ventricular hypertrophy, either <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a> or <a class="drug drug_general" data-topicid="9037" href="/z/d/drug information/9037.html" rel="external">dronedarone</a> is generally preferred to other antiarrhythmic agents. Our authors and reviewers have differing approaches, with some choosing amiodarone more often and others choosing dronedarone more often. (See <a class="local">'Left ventricular hypertrophy'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ambulatory monitoring </strong>– After the initiation of antiarrhythmic drug therapy, screening for drug-associated arrhythmia with ambulatory monitoring should be considered, particularly for patients at high risk of drug-induced arrhythmia. This includes those with baseline bradycardia or borderline QT prolongation, heart failure, or systolic left ventricular dysfunction. (See <a class="local">'Ambulatory monitoring'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Falk RH. Atrial fibrillation. N Engl J Med 2001; 344:1067.</a></li><li><a class="nounderline abstract_t">Connolly SJ. Appropriate outcome measures in trials evaluating treatment of atrial fibrillation. Am Heart J 2000; 139:752.</a></li><li><a class="nounderline abstract_t">Snow V, Weiss KB, LeFevre M, et al. Management of newly detected atrial fibrillation: a clinical practice guideline from the American Academy of Family Physicians and the American College of Physicians. Ann Intern Med 2003; 139:1009.</a></li><li><a class="nounderline abstract_t">Kühlkamp V, Schirdewan A, Stangl K, et al. Use of metoprolol CR/XL to maintain sinus rhythm after conversion from persistent atrial fibrillation: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 2000; 36:139.</a></li><li><a class="nounderline abstract_t">McNamara RL, Tamariz LJ, Segal JB, Bass EB. Management of atrial fibrillation: review of the evidence for the role of pharmacologic therapy, electrical cardioversion, and echocardiography. Ann Intern Med 2003; 139:1018.</a></li><li><a class="nounderline abstract_t">Lafuente-Lafuente C, Mouly S, Longás-Tejero MA, et al. Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation: a systematic review of randomized controlled trials. Arch Intern Med 2006; 166:719.</a></li><li><a class="nounderline abstract_t">Flaker G, Lopes RD, Hylek E, et al. Amiodarone, anticoagulation, and clinical events in patients with atrial fibrillation: insights from the ARISTOTLE trial. J Am Coll Cardiol 2014; 64:1541.</a></li><li><a class="nounderline abstract_t">Coplen SE, Antman EM, Berlin JA, et al. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials. Circulation 1990; 82:1106.</a></li><li><a class="nounderline abstract_t">Steeds RP, Birchall AS, Smith M, Channer KS. An open label, randomised, crossover study comparing sotalol and atenolol in the treatment of symptomatic paroxysmal atrial fibrillation. Heart 1999; 82:170.</a></li><li><a class="nounderline abstract_t">Plewan A, Lehmann G, Ndrepepa G, et al. Maintenance of sinus rhythm after electrical cardioversion of persistent atrial fibrillation; sotalol vs bisoprolol. Eur Heart J 2001; 22:1504.</a></li><li><a class="nounderline abstract_t">Wann LS, Curtis AB, January CT, et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (Updating the 2006 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2011; 57:223.</a></li><li><a class="nounderline abstract_t">Herweg B, Dalal P, Nagy B, Schweitzer P. Power spectral analysis of heart period variability of preceding sinus rhythm before initiation of paroxysmal atrial fibrillation. Am J Cardiol 1998; 82:869.</a></li><li><a class="nounderline abstract_t">Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2021; 42:373.</a></li><li><a class="nounderline abstract_t">European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery, Camm AJ, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace 2010; 12:1360.</a></li><li><a class="nounderline abstract_t">Piccini JP, Hasselblad V, Peterson ED, et al. Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation. J Am Coll Cardiol 2009; 54:1089.</a></li><li><a class="nounderline abstract_t">Roy D, Talajic M, Dorian P, et al. Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med 2000; 342:913.</a></li><li><a class="nounderline abstract_t">Singh BN, Singh SN, Reda DJ, et al. Amiodarone versus sotalol for atrial fibrillation. N Engl J Med 2005; 352:1861.</a></li><li><a class="nounderline abstract_t">AFFIRM First Antiarrhythmic Drug Substudy Investigators. Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM substudy of the first antiarrhythmic drug. J Am Coll Cardiol 2003; 42:20.</a></li><li><a class="nounderline abstract_t">Goldschlager N, Epstein AE, Naccarelli G, et al. Practical guidelines for clinicians who treat patients with amiodarone. Practice Guidelines Subcommittee, North American Society of Pacing and Electrophysiology. Arch Intern Med 2000; 160:1741.</a></li><li><a class="nounderline abstract_t">Vorperian VR, Havighurst TC, Miller S, January CT. Adverse effects of low dose amiodarone: a meta-analysis. J Am Coll Cardiol 1997; 30:791.</a></li><li><a class="nounderline abstract_t">Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347:1825.</a></li><li><a class="nounderline abstract_t">Zimetbaum P, Josephson ME. Is there a role for maintaining sinus rhythm in patients with atrial fibrillation? Ann Intern Med 2004; 141:720.</a></li><li><a class="nounderline abstract_t">European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery, Camm AJ, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31:2369.</a></li><li><a class="nounderline abstract_t">Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991; 324:781.</a></li><li><a class="nounderline abstract_t">Podrid PJ, Anderson JL. Safety and tolerability of long-term propafenone therapy for supraventricular tachyarrhythmias. The Propafenone Multicenter Study Group. Am J Cardiol 1996; 78:430.</a></li><li><a class="nounderline abstract_t">Podrid PJ, Lampert S, Graboys TB, et al. Aggravation of arrhythmia by antiarrhythmic drugs--incidence and predictors. Am J Cardiol 1987; 59:38E.</a></li><li><a class="nounderline abstract_t">Morganroth J, Anderson JL, Gentzkow GD. Classification by type of ventricular arrhythmia predicts frequency of adverse cardiac events from flecainide. J Am Coll Cardiol 1986; 8:607.</a></li><li><a class="nounderline abstract_t">Reiffel JA, Camm AJ, Belardinelli L, et al. The HARMONY Trial: Combined Ranolazine and Dronedarone in the Management of Paroxysmal Atrial Fibrillation: Mechanistic and Therapeutic Synergism. Circ Arrhythm Electrophysiol 2015; 8:1048.</a></li><li><a class="nounderline abstract_t">Maisel WH, Kuntz KM, Reimold SC, et al. Risk of initiating antiarrhythmic drug therapy for atrial fibrillation in patients admitted to a university hospital. Ann Intern Med 1997; 127:281.</a></li><li><a class="nounderline abstract_t">Hauser TH, Pinto DS, Josephson ME, Zimetbaum P. Safety and feasibility of a clinical pathway for the outpatient initiation of antiarrhythmic medications in patients with atrial fibrillation or atrial flutter. Am J Cardiol 2003; 91:1437.</a></li><li><a class="nounderline abstract_t">Lafuente-Lafuente C, Longas-Tejero MA, Bergmann JF, Belmin J. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev 2012; :CD005049.</a></li><li><a class="nounderline abstract_t">Kirchhof P, Andresen D, Bosch R, et al. Short-term versus long-term antiarrhythmic drug treatment after cardioversion of atrial fibrillation (Flec-SL): a prospective, randomised, open-label, blinded endpoint assessment trial. Lancet 2012; 380:238.</a></li><li><a class="nounderline abstract_t">Connolly SJ, Camm AJ, Halperin JL, et al. Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med 2011; 365:2268.</a></li><li class="breakAll">http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2011/09/news_detail_001344.jsp&amp;murl=menus/news_and_events/news_and_events.jsp&amp;mid=WC0b01ac058004d5c1.</li><li class="breakAll">http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm264204.htm.</li><li class="breakAll">http://www.fda.gov/Drugs/DrugSafety/ucm240011.htm.</li><li><a class="nounderline abstract_t">January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation 2014; 130:e199.</a></li><li><a class="nounderline abstract_t">January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation 2014; 130:2071.</a></li><li><a class="nounderline abstract_t">January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons. Circulation 2019; 140:e125.</a></li></ol></div><div id="topicVersionRevision">Topic 1035 Version 65.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11287978" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10783204" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Appropriate outcome measures in trials evaluating treatment of atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14678921" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Management of newly detected atrial fibrillation: a clinical practice guideline from the American Academy of Family Physicians and the American College of Physicians.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10898425" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Use of metoprolol CR/XL to maintain sinus rhythm after conversion from persistent atrial fibrillation: a randomized, double-blind, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14678922" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Management of atrial fibrillation: review of the evidence for the role of pharmacologic therapy, electrical cardioversion, and echocardiography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16606807" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation: a systematic review of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25301455" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Amiodarone, anticoagulation, and clinical events in patients with atrial fibrillation: insights from the ARISTOTLE trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2144796" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10409530" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : An open label, randomised, crossover study comparing sotalol and atenolol in the treatment of symptomatic paroxysmal atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11482924" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Maintenance of sinus rhythm after electrical cardioversion of persistent atrial fibrillation; sotalol vs bisoprolol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21177058" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (Updating the 2006 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9781969" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Power spectral analysis of heart period variability of preceding sinus rhythm before initiation of paroxysmal atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32860505" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20876603" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19744618" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10738049" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15872201" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Amiodarone versus sotalol for atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12849654" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM substudy of the first antiarrhythmic drug.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10871966" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Practical guidelines for clinicians who treat patients with amiodarone. Practice Guidelines Subcommittee, North American Society of Pacing and Electrophysiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9283542" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Adverse effects of low dose amiodarone: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12466506" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : A comparison of rate control and rhythm control in patients with atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15520430" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Is there a role for maintaining sinus rhythm in patients with atrial fibrillation?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20802247" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1900101" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8752188" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Safety and tolerability of long-term propafenone therapy for supraventricular tachyarrhythmias. The Propafenone Multicenter Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2437788" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Aggravation of arrhythmia by antiarrhythmic drugs--incidence and predictors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3745706" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Classification by type of ventricular arrhythmia predicts frequency of adverse cardiac events from flecainide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26226999" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : The HARMONY Trial: Combined Ranolazine and Dronedarone in the Management of Paroxysmal Atrial Fibrillation: Mechanistic and Therapeutic Synergism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9265427" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Risk of initiating antiarrhythmic drug therapy for atrial fibrillation in patients admitted to a university hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12804730" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Safety and feasibility of a clinical pathway for the outpatient initiation of antiarrhythmic medications in patients with atrial fibrillation or atrial flutter.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22592700" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22713626" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Short-term versus long-term antiarrhythmic drug treatment after cardioversion of atrial fibrillation (Flec-SL): a prospective, randomised, open-label, blinded endpoint assessment trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22082198" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Dronedarone in high-risk permanent atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22082198" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Dronedarone in high-risk permanent atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22082198" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Dronedarone in high-risk permanent atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22082198" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Dronedarone in high-risk permanent atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24682347" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24682348" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30686041" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
